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Objective. This study was aimed to study tissue distribution and tumor imaging potential of 68Ga-glycopeptide (GP) in tumor-
bearing rodents by PET. Methods. GP was synthesized by conjugating glutamate peptide and chitosan. GP was labeled with 68Ga
chloride for in vitro and in vivo studies. Computer outlined region of interest (counts per pixel) of the tumor and muscle (at the
symmetric site) was used to determine tumor-to-muscle count density ratios. To ascertain the feasibility of 68Ga-GP in tumor
imaging in large animals, PET/CT imaging of 68Ga-GP and 18F-FDG were conducted in New Zealand white rabbits bearing VX2
tumors. Standard uptake value of tumors were determined by PET up to 45min. To determine blood clearance and half-life
of 68Ga-GP, blood samples were collected from 10 seconds to 20min. Results. Radiochemical purity of 68Ga-GP determined by
instantthin-layerchromatographywas>95%.Tumoruptakevalues(SUV)for 68Ga-GPand 18F-FDG inNewZealandwhite rabbits
bearing VX2 tumors were 3.25 versus 7.04. PET images in tumor-bearing rats and rabbits conﬁrmed that 68Ga-GP could assess
tumor uptake. From blood clearance curve, the half-life of 68Ga-GP was 1.84hr. Conclusion Our data indicate that it is feasible to
use 68Ga-GP to assess tumor angiogenesis.
1.Introduction
With progress of molecular biology in recent years, imaging
techniques are undergoing tremendous development and
improvement. These imaging modalities play a major role
in the development of novel therapies, since they generate
information about target expression as well as function,
pathway activity, and cell migration in the intact organism.
For instance, angiogenesis, the proliferation of endothelial
and smooth muscle cells to form new blood vessels, is
an essential component of the metastatic pathway. These
vessels provide the principal route by which tumor cells
exit the primary tumor site and enter the circulation. For
many tumors, the vascular density can provide a prognostic
indicator of metastatic potential, with the highly vascular
tumors having a higher incidence of metastasis than poorly
vascular tumors [1]. Experimental research suggests that it is
possible to block angiogenesis by speciﬁc inhibitory agents,
and that modulation of angiogenic activity is associated
with tumor regression in animals with diﬀerent types of
neoplasia.The promisingangiosuppressive agentsforclinical
testing are naturally occurring inhibitors of angiogenesis
(angiostatin, endostatin, platelet factor-4, and others). Mea-
suring angiogenesis (blood vessel density) and/or its main
regulators suchas vascular endothelialgrowthfactor (VEGF)
and basic ﬁbroblast growth factor (bFGF), or the levels of
apoptosis after treatment in solid tumors provides new and
sensitive markers for tumor progression, metastasis, and
prognosis [2, 3].
Polysaccharides such as heparin, chitosan, and chon-
droitin play a potent role in tumor growth, tissue repair, and
angiogenesis. Chitosan, an angiogenesis biomer, interacts2 Journal of Biomedicine and Biotechnology
with vascular endothelia cells and potentiates the ﬁbrob-
last growth factor (FGF-2) activity. Chitosan is known as
a wound-dressing and tissue-adhesive material showing bio-
compatibility, anti-infective activity, and the ability to accel-
erate wound healing [4–6]. During the healing process, chi-
tosan enhances macrophage activation, cytokine (IL-8) pro-
duction by macrophages and ﬁbroblasts, anti-inﬂammatory
action, angiogenesis stimulation, granulation, and scar for-
mation. Though chitosan has made outstanding advantage
in the ﬁeld of angiogenesis, some signiﬁcant limitations still
remain in the treatment of cancer via intracellular delivery
of cytotoxic drugs. In order to enhance therapeutic index
of chitosan in cancer treatment, we conjugated glutamate
peptide with chitosan.
The excitatory amino acid glutamate (Glu) is a potent
neurotransmitter in the central nervous system and exerts
its action via a variety of glutamate transporters [7]. It is
known that cellular uptake of polyglutamate peptide (GAP)
is speciﬁc to glutamate transporter [8]. Chain of 5 or more
glutamic acids could reduce renal uptake in animal models
[9]. Conjugation of GAP with chitosan resulting in GP
would be a novel agent to target tumor vascular and cellular
component. Radiolabeled GP would support this concept.
Imaging science enables the comprehensive characteriza-
tion of therapeutic intervention and can be used in pre-
clinical studies, pharmacokinetic studies, dose-ﬁnding stud-
ies, and proof-of-concept studies. Positron emission tomog-
raphy (PET) and single photon emission computed tomog-
raphy (SPECT) permit mapping and measuring the rate
of physiological, biochemical, and molecular processes with
radiolabeled compounds and appropriate tracer kinetic
models. Cellular imaging by PET and SPECT provides
valuableinformation in monitoring and guiding clinical trial
using cell-based therapies in the treatment of malignant
and other diseases. 68Ga and 99mTc are the most attractive
radiometals obtained from generators for PET and SPECT
clinical applications due to their energy (511 and 140keV),
half-life (68min and 6h), and simple coordination chem-
istry. We previously have reported that glycopeptide (GP),
a copolymer of chitosan and glutamate peptide, provides
an opportunity to target tumor vasculature and cellular via
glutamate transporters [10]. In vitro assays revealed that cell
uptake of 99mTc-GP was via glutamate transporters. 99mTc-
GPwasabletomeasuretumoruptakechangesafterpaclitaxel
treatment. Biodistribution of 99mTc-GP showed increased
tumor-to-tissue count density ratios as a function of time.
Planar images conﬁrmed that it is feasible to use 99mTc-GP
to assess tumor angiogenesis. To evaluate whether GP could
also be labeled with a diﬀerent isotope for PET imaging of
tumors, here, we report the tissue distribution and tumor
imaging potential of 68Ga-GP.
2.Materialsand Methods
2.1. Synthesis of 68Ga-Glycopeptide (GP). To a stirred solu-
tion of chitosan (200mg, MW 3,500–5,000) in water (4mL)
and 3-ethyl-3-(3-dimethylaminopropyl) carbodiimide-HCl
(EDC) (128.5mg, 0.67mmoL) (Pierce Chemical Company,
Rockford, IL) was added. Glutamate peptide sodium salt
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Figure 1: Structure of glycopeptide (GP).
Table 1: Biodistribution of 68Ga-GP in breast tumor-bearing Rats.
% of injected dose per gram of tissue weight (n = 3/time, interval,
iv)∗.
30min 60min 120min
Blood 2.61 ± 0.18 1.81 ± 0.05 1.37 ± 0.05
Heart 0.59 ± 0.06 0.43 ± 0.02 0.32 ± 0.02
Lung 2.34 ± 0.45 2.58 ± 0.16 1.38 ± 0.06
Thyroid 1.10 ± 0.11 1.40 ± 0.87 0.59 ± 0.06
Pancreas 0.38 ± 0.03 0.34 ± 0.04 0.28 ± 0.02
Liver 3.81 ± 0.32 4.83 ± 0.54 4.94 ± 0.38
Spleen 2.13 ± 0.07 2.65 ± 0.14 2.97 ± 0.11
Kidney 1.35 ± 0.02 1.36 ± 0.01 1.41 ± 0.11
Stomach 0.58 ± 0.04 0.65 ± 0.07 0.74 ± 0.18
Intestine 0.54 ± 0.12 0.53 ± 0.07 0.78 ± 0.22
Uterus 0.70 ± 0.02 0.65 ± 0.05 0.57 ± 0.03
Tumor 0.68 ± 0.12 0.89 ± 0.10 1.18 ± 0.09
Muscle 0.12 ± 0.02 0.12 ± 0.00 0.10 ± 0.02
Bone 0.45 ± 0.12 0.46 ± 0.09 0.59 ± 0.03
Brain 0.08 ± 0.01 0.07 ± 0.01 0.07 ± 0.01
Tumor/blood 0.26 ± 0.03 0.49 ± 0.07 0.86 ± 0.09
Tumor/muscle 6.12 ± 1.87 7.20 ± 0.83 13.26 ± 4.41
∗Value shown represent the mean ± standard deviation of data from 3
animals at (Count at 460–560keV window).
(200mg, MW 1,308) was then added. The mixture was
stirred at room temperature for 24hr. The mixture was
dialyzed for 48hr using Spectra/POR molecular porous
membrane with cutoﬀ at 5,000 (Spectrum Medical Indus-
tries Inc., Houston, TX). After dialysis, the product was
ﬁltered and dried using a freeze dryer (Labconco, Kansas
C i t y ,M O ) .T h eG Pi nt h es a l tf o r mw e i g h e d3 2 0 m g .T h e
chemical structure is shown in Figure 1. Gel permeation
chromatogram (GPC) and capillary electrophoresis (CE)
were used to analyze the purity of GP.Journal of Biomedicine and Biotechnology 3
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Figure 2: Gel permeation chromatogram (GPC) analysis of GP
showed the purity of GP was greater than 95%. The spectrum
showedtheretentiontimeof9.645minandtheestimatedmolecular
weight of 7,484.
2.2. Radiolabeling of GPwith 68Ga. Radiolabeling ofGP with
68Ga was performed in a standard manner [11]; brieﬂy, GP
(5mg) was dissolved in 0.2ml of water, and 68Ga chloride
(5mCi) evaporated to dryness and reconstituted in 0.1ml
of sterilized water at room temperature, followed by heating
up to 55◦C for 10min. Radiochemical purity was deter-
mined by instant thin-layer chromatography (ITLC Silica-
Gel coated, Gelman Sciences, Ann Arbor, MI) eluted with
saline.
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Figure 3:Capillaryelectrophoresis (CE) analysisofGP. Thespectra
showed that the purity of GP was greater than 95%.
Table 2: Biodistribution of FDG in breast tumor-bearing rats.% of
injected dose per gram of tissue weight (n = 3/time, interval, i.v.)∗.
30min 60min 120min
Blood 0.40 ± 0.04 0.13 ± 0.01 0.06 ± 0.00
Heart 1.57 ± 0.06 1.38 ± 0.13 1.08 ± 0.07
Lung 0.55 ± 0.06 0.42 ± 0.02 0.46 ± 0.03
Thyroid 1.07 ± 0.08 1.04 ± 0.04 1.05 ± 0.07
Pancreas 0.26 ± 0.03 0.21 ± 0.01 0.20 ± 0.02
Liver 0.40 ± 0.05 0.16 ± 0.01 0.13 ± 0.01
Spleen 0.82 ± 0.08 0.74 ± 0.03 0.86 ± 0.07
Kidney 0.71 ± 0.05 0.37 ± 0.01 0.24 ± 0.02
Stomach 0.61 ± 0.08 0.44 ± 0.03 0.39 ± 0.03
Intestine 0.69 ± 0.07 0.53 ± 0.03 0.52 ± 0.02
Uterus 0.51 ± 0.04 0.42 ± 0.03 0.41 ± 0.03
Tumor 2.13 ± 0.11 2.49 ± 0.08 2.03 ± 0.18
Muscle 0.33 ± 0.04 0.34 ± 0.03 0.74 ± 0.02
Bone 0.33 ± 0.04 0.44 ± 0.06 0.50 ± 0.03
Brain 2.00 ± 0.15 1.99 ± 0.05 1.39 ± 0.09
Tumor/blood 5.19 ± 0.38 19.78 ± 1.37 34.37 ± 1.76
Tumor/muscle 5.88 ± 0.57 7.54 ± 0.56 2.87 ± 0.24
∗Value shown represent the mean ± standard deviation of data from 3
animals at (Count at 460–560keV window).
2.3. In Vitro Stability Assays of 68Ga-GP. 68Ga-GP was pre-
pared in the concentration of 5mg/1mCi/ml. 0.1mL of
68Ga-GP was incubated with 0.1mL phosphate buﬀered
saline (pH = 7.4) at 37◦C for 30–120min. In vitro stability
of 68Ga-GP was determined by chromatographic analysis, as
described in the above section. There was no breakdown of
68Ga-GP up to 2hr.
2.4. Biodistribution Studies. Female Fischer 344 rats (150–
175g) (Harlan Sprague-Dawley, Inc., Indianapolis, IN) were
inoculated subcutaneously in the right leg with breast cancer
cells (106 cells in 0.1mL/rat) from the 13762 cell line
(known as DMBA-inducedbreast cancer cell line). Biodistri-
bution studies were performed on day 14 after inoculation.4 Journal of Biomedicine and Biotechnology
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Figure 4: 68Ga-GP was prepared in the concentration of
5mg/1mCi/1mL. 0.1mL of 68Ga-GP was incubated with 0.1mL
phosphate buﬀered saline (pH = 7.4) at 30–120min. There was no
breakdown of 68Ga-GP up to 120min.
A group of Female Fischer 344 tumor-bearing rats was
injected intravenously with 68Ga-GP or 18F-FDG(30μCi/rat,
n = 3 rats/time point) through the tail vein. The injected
mass was 30μgo f68Ga-GP per rat. At 30, 60, and
120min following administration of the radiotracers, the
animals were sacriﬁced, and the tumor and selected tissues
were excised, weighed, and counted for radioactivity with
a gamma counter (Packard Instruments, Downers Grove,
IL). The biodistribution of 68Ga-GP or 18F-FDG in each
sample was calculated as a percentage of the injected dose
per gram of the tissue’s wet weight (%ID/g).
2.5. MIRD Dosimetry Estimates. Rat absorbed doses esti-
mates for 68Ga-GP were computed from their respective
biodistribution data. Fitted residence time functions were
plotted and multiplied by the exponential decay functions
Table 3: Radiation dose estimates of reference adult for 68Ga-GP
from rabbits.
Organs (5rem annual/15rem total)
Target organ rad/mCi Human dose (mCi) rad
adrenals 2.54E− 04 20 0.005
brain 7.37E− 06 20 0.000
breasts 2.78E− 04 20 0.006
gall bladder wall 1.03E− 04 20 0.002
lli wall 8.24E− 06 20 0.000
small int 2.34E− 05 20 0.000
stomach 1.69E− 04 20 0.003
uli wall 3.02E− 05 20 0.001
heart wall 2.30E− 02 20 0.460
kidneys 7.92E− 05 20 0.002
liver 2.13E− 04 20 0.004
lungs 4.62E− 04 20 0.009
muscle 9.27E− 05 20 0.002
pancreas 2.54E− 04 20 0.005
bone surfaces 8.54E− 05 20 0.002
skin 4.65E− 05 20 0.001
testes 2.09E− 06 20 0.000
thymus 8.81E− 04 20 0.018
thyroid 5.34E− 05 20 0.001
urine bladder wall 5.92E− 06 20 0.000
uterus 1.11E− 05 20 0.000
eﬀ dose 1.48E− 04 20 0.003
Blood-forming organs (3rem annual/5rem total)
ovaries 1.16E− 05 20 0.000
red marrow 1.29E− 04 20 0.003
spleen 1.18E− 04 20 0.002
eﬀ dose eq 1.60E− 03 20 0.032
total body 1.92E− 04 20 0.004
(i.e., half-life) for 68Ga-GP. These functions were then
integrated analytically to determine the area under the
c u r v e( A U C )t oy i e l dt h er e s i d e n c et i m eo fe a c ho r g a n .
It was assumed that the injected activity distribution was
uniformly distributed throughout the body immediately
following injection. It was further assumed that no excretion
occurred after the last time point and that the activity
distribution remained unchanged after this time point; that
is, no biological excretion was assumed after the last time
point. Mass correction factors were used to account for the
diﬀerentratiosoforgantototalbodyweightsintheratandin
humans and allowed forthe scaling ofthe rat residence times
to human residence times. For the organs where total organ
weight was unavailable, the organ weights derived from the
Cristy-Eckerman mathematic phantoms for the adult male
were used to estimate total tissue activity. Residence times
were then used to calculate target organ absorbed radiation
doses with S-value tables for a standard 70kg male model
using the MIRDose Olinda software package (Oakridge,
TN). Each organ dose was computed from the sum of self-
dose plus the dose it received from each source organ inJournal of Biomedicine and Biotechnology 5
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Figure 5: Dynamic mPET Imaging of 68Ga-GP (a) and 18F-FDG (b) in breast tumor bearing rats (0.003mg, 600uCi/rat, iv) at 0–20min
showed tumor could be visualized by both compounds.
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Figure 6: PET whole body at 45min in New Zealand white rabbits
bearing VX2 tumors.
the body or from the remainder of the body. The estimated
human radiation absorption dose was determined.
2.6.PETImaging Studies. FormicroPETimaging,theimages
were acquired on a microPET R4 scanner, a dedicated 3D
small-animal PET (Concorde Microsystems, Knoxville TN).
A group of female Fischer 344 tumor-bearing rats was
injected intravenously with 68Ga-GP or 18F-FDG (n = 3
rats/compound) through the tail veins. Each animal will
be anesthetized and secured onto the microPET. Cradle
notches, laser lights, and animal felt pen markings will be
used to ensure reproducible animal positioning before and
after administration of 68Ga-GP and 18F-FDG. Each animal
will thenbe injected with 1.62μCi/g body weight of 68Ga-GP
and 18F-FDGandimagedfor2hrinadynamicmode.Amin-
imum of ∼20 million events will be acquired in 120 minutes
covering the tumor bearing area. The acquired list mode
data will then be histogramed into frames of varying dura-
tions using Fourier rebinning. The corresponding images
will bereconstructedinto128∗128∗63(0.72∗0.72∗1.3mm)
matrix using ordered subset expectation maximization tech-
niques. All corrections for attenuation, scatter, dead-time,
and randomizations were applied to generate quantiﬁable
images. Computer-outlined region of interest (counts per
pixel) of the tumor and muscle (at the symmetric site) was
used to determine tumor-to-muscle count density ratios.6 Journal of Biomedicine and Biotechnology
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Figure 7: 45minutes dynamic imagewith PET-CTof 68Ga-GP in a New Zealandwhite rabbit bearing VX2 tumor showed SUV ofthe tumor
was 3.25.
For PET/CT imaging in large animals, New Zealand
whiterabbitswereinoculatedwithVX-2tumormass(rabbit-
driven squamous tumors). The rabbits were administered
intravenously (iv) 2mCi of 68Ga-GP and 18F-FDG (control).
The images were acquired on a dedicated Advance 3D
PET/CT (GE Medical system) at 0.5–2hr after i.v. injection
of the radiotracers. Standard uptake value of tumors was
determined by dynamic PET up to 45min.
2.7. Kinetic Study of Blood Clearance of 68Ga-GP in New
Zealand White Rabbit. New Zealand white rabbits were
administered intravenously (iv) 2mCi of 68Ga-GP. To deter-
mine blood clearance and half-life of 68Ga-GP, 0.1ml blood
samples were collected from 10 seconds to 20min (14
time points) after injection. Blood samples were weighted,
and the radioactivities were counted by gamma counter
(Packard Instruments, Downers Grove, IL). The radioac-
tivity of each sample was calculated as a percentage of
the injected dose per gram of the blood’s net weight
(%ID/g).
3.Results
3.1. Chemistry. Elemental analysis of GP (C11H14N2Na2O6,
C, H, N)showed C: 41.54,H: 10:62, and N: 7.19.(calculated
C: 41.77, H: 8.86, and N: 4.43). The estimated purity of GP
was greater than 95% (based upon carbon content). Gel per-
meation chromatogram (GPC) and capillary electrophoresis
(CE) spectra showed that the purity of GP was greater
than 95% (Figures 2 and 3). From radio-TLC (Bioscan,
Washington, DC) analysis, the radiochemical purity was
more than 95% (Rf = 0.1). In vitro stability assays indicated
that the radiation yield is 98.67% at 30min and 97.73% at
2hr after labeling. There was no breakdown 68Ga-GP up to
2hr(Figure 4).
3.2.BiodistributionStudies. Therewasanincreaseduptakein
tumors (percent of injected dose per gram of tissue), tumor-
to-blood and tumor-to-muscle count density ratios by 68Ga-
GP at 0.5–2hr, whereas the optimum tumor uptake and
tumor-to-muscle count density ratios for 18F-FDG were at
1hrafteradministrations (Tables1and2).InbiodistributionJournal of Biomedicine and Biotechnology 7
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Figure 8: 45 minutes dynamic image with PET-CT of 18FDG in New Zealand white rabbit bearing VX2 tumor showed SUV of the tumor
was 7.04.
studies at 30, 60, and 120min, tumor uptake values,
tumor/blood, and tumor/muscle ratios for 68Ga-GP were
0.68 ± 0.12 to 1.18 ± 0.09, 0.26 ± 0.03 to 0.86 ± 0.09, and
6.12 ± 1.87 to 13.26 ± 4.41 and for 18F-FDG were 2.03 ±
0.18 to 2.49 ± 0.08, 5.19 ± 0.38 to 34.37 ± 1.76, and 2.87 ±
0.24 to 7.54 ± 0.56, respectively (Tables 1 and 2).
3.3.MIRDDosimetryEstimates. Therabbitimagingdatawas
used to calculate residence times for each organ through
analytical integration. The residence times were scaled from
rabbit to human (70kg reference adult model) using organ
correction factors to generate human residence time esti-
mates.Thekidneysandspleenaretheprimaryandsecondary
contributors for 68Ga-GP, respectively. The MIRD output
was multiplied by a proposed human dose of 20mCi for
68Ga-GP to yield total absorbed dose shown in Table 3. 68Ga-
GP showed total rad absorbed by each organ was below the
proposed annual and total limits. Radiation exposure to the
whole body, blood-forming organs (redmarrow and spleen),
gonads (testes and ovaries), and eﬀective dose equivalent for
the proposed human single dose at 20mCi fall below the
limits of 3rad annually and 5rad total. The absorbed dose
in all other organs (e.g., kidneys) was below the limits of
single dose of 5rad annually and 15rad total(Table 3).These
radiation exposure values are commonly accepted as criteria
for in vivo radiation safety measurement.
3.4. PET Imaging Studies. Tumors could be well visualized
both in breast tumor-bearing rats and VX-2 tumor-bearing
rabbits (Figures 5 and 6). From PET image ROI analysis,
standard tumor uptake values (SUVs) for 68Ga-GP and 18F-
FDG in VX-2 tumor-bearing rabbits were 3.25 and 7.04,
respectively (Figures 7 and 8). PET images in tumor-bearing
rats and rabbits conﬁrmed that 68Ga-GP could assess tumor
uptake. PET dynamic scan showed fast tumor uptake of
68G a - G Pi naN e wZ e a l a n dw h i t er a b b i tb e a r i n gV X 2t u m o r
(Figure 9).Furthermore,thereisnointestine uptakein 68Ga-
GP PET imaging indicated the radioisotope labeling of 68Ga-
GP is stable in vivo.
3.5. Kinetic Study of Blood Clearance of 68Ga-GP in New
Zealand White Rabbit. The blood clearance of 68Ga-GP
showed both distribution phase and elimination phase
(Figure 10(a)). The elimination phase was used to calculate8 Journal of Biomedicine and Biotechnology
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Figure 9: 45 Minutes dynamic tumor uptake of 68Ga-GP in a New
Zealandwhite rabbit bearing VX2 tumor. The axialview from PET-
CT showed the location of tumor.
the half-life (T1/2) of 68Ga-GP (Figure 10(b)). Regression
line formulation (y =− 0.0018x +0 .3967, R2 = 0.8375)
was estimated using Microsoft Oﬃce Excel 2003. The T1/2
of 68Ga-GP was 1.84hr and the elimination rate constant (k)
was 0.377hr−1.
4.Discussion
Chitosan, a cationic biopolymer derived by deacetylation of
chitin. Chitin and chitosan derivatives are used as excipients
and drug carriers in the pharmaceutical ﬁeld. For instance,
ﬁlms prepared using chitin or chitosan have been devel-
oped as wound dressings, oral mucoadhesive, and water-
resisting adhesivebyvirtueoftheirreleasecharacteristics and
adhesion. Intratumoral administration of gadopentetic acid-
chitosan complex nanoparticles (approximately 430nm in
diameter) has been more eﬀective for gadolinium neutron-
capture therapy compared with a group treated with the
solution. Chitin and chitosan derivatization contributed to
expansion of application in drug delivery and sustained drug
release [12–14]. It has been reported that chitosan could
directly conjugate drugs or be modiﬁed by the introduction
of thioglycolic acid (TGA) resulting in chitosan-TGA con-
jugates with thiol groups. Chitosan-thioglycolic acid conju-
gates has been found to be a promising candidate in tissue
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Figure 10: Blood clearance (a) and half-life analysis (one compart-
ment) of 68Ga showed the half-life of 68Ga-GP was 1.84hr with K
value of 0.377hr.
engineering due to their physicochemical properties [15].
Despite the broadened application of chitosan derivatives,
one major limitation of chitosan is lack of cellular targeting.
Previous studies have shown that glutamate peptide is
a candidate of drug carrier [16, 17]. Radiolabeled glutamic
acid has shown to be useful in tumor cellular imaging [18].
To optimize the intracellular uptake of chitosan derivatives,
we have synthesized glutamate peptide, chitosan, and a GP
copolymer. This copolymer would be ideal to conjugate the
drugs with either amino or acid groups which provides
an advantage over either chitosan or glutamate peptide. In
addition, results from our previous in vitro cellular uptake
and animal imaging studies showed that GP is a target
drug carrier via glutamate transporters [10]. This targeted
drug carrier may provide an advantage not only to improve
drug solubility but also to overcome drug resistance during
chemotherapy.
In our previous ﬁndings, 99mTc-GP was able to measure
uptake diﬀerences after cells treated with paclitaxel andJournal of Biomedicine and Biotechnology 9
uptake diﬀerence between tumor and inﬂammation. In vitro
cellular uptake assay indicated that cellular uptake of 99mTc-
GP was via glutamate transporters. In this study, we further
tested the 68Ga-GP imaging using PET/CT.
In summary, PET imaging studies indicated that it is
feasible touse 68Ga-GP to image tumors. GP has multiamino
and acid groups which broaden its chemistry application.
5.Relevance
Atpresent,thereisnoangiogenesisimaging agentfocusedon
both vascular endothelial adhesiveness and cellular targets.
GP interacts with vascular endothelial and cellular targets.
GP also has multiple amino and carboxylic groups, which
allows anticancer drug conjugate for targeted imaging and
therapy.Ourdata indicatethat 68Ga-GP accumulatesactively
in tumors both in small and large animal models (Figures 4
and 5). The imaging data obtained from 68Ga-GP not only
provide an impact on improving the diagnosis of cancer
but also provide a basis for internal radionuclide targeted
therapy.
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